Table 3.
Antiarrhythmic Medication Use
| Frequency | Mean Duration (Months) | |||
|---|---|---|---|---|
| GD Group | NGD Group | GD Group | NGD Group | |
| First prescribed antiarrhythmic medication | ||||
| N | 3056 | 2920 | 30.3 | 21.8 |
| Flecainide | 454 (14.9%) | 91 (3.1%) | 32.0 | 24.6 |
| Propafenone | 297 (9.7%) | 99 (3.4%) | 32.0 | 26.8 |
| Amiodarone | 749 (24.5%) | 1517 (52.0%) | 22.3 | 20.4 |
| Dofetilide | 245 (8.0%) | 294 (10.1%) | 34.3 | 31.6 |
| Sotalol | 1311 (42.9%) | 407 (13.9%) | 33.1 | 26.1 |
| Dronedarone | 0 | 488 (16.7%) | 15.1 | |
| Disopyramide | 0 | 15 (0.5%) | 21.3 | |
| Procainamide | 0 | 4 (0.1%) | 16.7 | |
| Quinidine | 0 | 5 (0.2%) | 24.7 | |
| P value | <0.001 | <0.001 | ||
| Second prescribed antiarrhythmic medication | ||||
| N | 562 (18.4%) | 794 (27.2%) | 19.5 | 15.8 |
| Flecainide | 82 (14.6%) | 77 (9.7%) | 23.5 | 16.8 |
| Propafenone | 30 (5.3%) | 36 (4.5%) | 21.8 | 17.8 |
| Amiodarone | 226 (40.2%) | 213 (26.8%) | 14.8 | 14.8 |
| Dofetilide | 169 (30.1%) | 114 (14.4%) | 23.8 | 15.9 |
| Sotalol | 55 (9.8%) | 173 (21.8%) | 18.2 | 18.1 |
| Dronedarone | 0 | 172 (21.7%) | 14.2 | |
| Disopyramide | 0 | 6 (0.8%) | 12.0 | |
| Procainamide | 0 | 2 (0.3%) | 14.6 | |
| Quinidine | 0 | 1 (0.1%) | 5.7 | |
| P value | <0.001 | <0.001 | ||
GD indicates guideline‐directed group; NGD, non–guideline directed group.